Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
about
Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity.Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.Tenofovir Alafenamide: A Review in Chronic Hepatitis B.Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.The US Food and Drug Administration's tentative approval process and the global fight against HIV.Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.Harnessing nanostructured systems for improved treatment and prevention of HIV diseaseDarunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
P2860
Q38714018-2D465D14-EF30-433D-8A96-ED8FBD8022EAQ39002230-3915FF5C-DAF2-4EC3-B474-C61F9FFA7FA7Q39074109-E84EE532-8982-4484-8A7B-8FD8F1013208Q39298139-6B4F0C51-8B44-4CEA-939A-B6DF6F36523DQ41927231-305B37FD-EE34-4A1E-B69D-2167BF21351AQ47142298-084D6670-26FA-4D66-9FB5-69AFCFEFC22DQ47560453-D2AB46F4-EB65-4022-B210-D9C34884C9AAQ48019035-5C3F2AF6-9192-4A5D-BBA5-31C7B0CB3033Q50059498-1C1D97EA-BA9E-459F-9F1E-0AF08E67160EQ56992437-F61002C1-6B51-4B1B-9779-CD0D199AB7FAQ59126145-4B56EA74-0216-4E86-A7F0-962C28A57CBD
P2860
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and Safety of ...... s with Severe Renal Impairment
@en
Pharmacokinetics and Safety of ...... with Severe Renal Impairment.
@nl
type
label
Pharmacokinetics and Safety of ...... s with Severe Renal Impairment
@en
Pharmacokinetics and Safety of ...... with Severe Renal Impairment.
@nl
prefLabel
Pharmacokinetics and Safety of ...... s with Severe Renal Impairment
@en
Pharmacokinetics and Safety of ...... with Severe Renal Impairment.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and Safety of ...... s with Severe Renal Impairment
@en
P2093
Brian P Kearney
Joseph M Custodio
Kah Hiing J Ling
Marshall Fordyce
Mona Vimal
Srinivasan Ramanathan
William Garner
P2860
P304
P356
10.1128/AAC.00005-16
P407
P577
2016-05-23T00:00:00Z